Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amiselimod in Relapsing-Remitting Multiple Sclerosis (MT-1303-E05)
NCT01890655Phase 2Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Aug 2013
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 17
01
Overview
A Phase 2 trial of amiselimod in relapsing-remitting multiple sclerosis (RRMS), sponsored by Mitsubishi Tanabe Pharma Corporation. Started Aug 2013; status: completed.
02
Drugs
amiselimod
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT01890655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01890655.